Back to Archived Journals » Biosimilars » Volume 6 » default
Biosimilars ceased publishing in October 2016. All new submissions can be made to Biologics: Targets and Therapy. All articles that have been published in Biosimilars will continue to be available on the Dove Press site, and will be securely archived with CLOCKSS.
Biosimilars
ISSN: 2230-245X
- View all (31)
- Volume 6, 2016 (6)
- Volume 5, 2015 (9)
- Volume 4, 2014 (4)
- Volume 3, 2013 (6)
- Volume 2, 2012 (4)
- Volume 1, 2011 (2)
Archive: Volume 6, 2016
Physicochemical and biological comparison of the first Brazilian biosimilar filgrastim with its reference product
Mantovani M, Caruso CS, Facchini FDA, Pascon R, Cagnacci PRV, de Magalhães VD
Biosimilars 2016, 6:45-60
Published Date: 30 August 2016
Adalimumab: a review of the reference product and biosimilars
Azevedo VF, Troiano LDC, Galli NB, Kleinfelder A, Catolino NM, Martins PCU
Biosimilars 2016, 6:29-44
Published Date: 26 July 2016
"Step" versus "phase" in the clinical development of biosimilars: the correct noun holds the key to success
Ewesuedo R
Biosimilars 2016, 6:25-28
Published Date: 22 June 2016
Tools for the analysis and characterization of therapeutic protein species
Fuh MM, Steffen P, Schlüter H
Biosimilars 2016, 6:17-24
Published Date: 5 May 2016
Considerations in biosimilar insulin device development
Fry AR, Krentz AJ, Hompesch M
Biosimilars 2016, 6:9-15
Published Date: 16 February 2016
Development, safety, and efficacy of biosimilar adalimumab: the data so far
Gabbani T, Deiana S, Bagnoli S, Annese V
Biosimilars 2016, 6:1-7
Published Date: 29 January 2016